A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 11, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

December 31, 2028

Conditions

Stargardt DiseaseStargardt Macular DegenerationStargardt Macular Dystrophy

Interventions

GENETIC

SB-007

Subretinal Administration of SB-007

Trial Locations (5)

RECRUITING

Bascom Palmer Eye Institute, Miami

RECRUITING

Retina Foundation of the Southwest, Dallas

RECRUITING

UCHealth Sue Anschutz-Rodgers Eye Center,, Aurora

RECRUITING

Oregon Health & Science University, Portland

RECRUITING

Massachusetts Eye and Ear Infirmary, Boston

All Listed Sponsors

lead

Splice Bio

INDUSTRY